查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1595632

前列腺保健市场：按疾病类型、治疗类型、药物治疗类型划分 - 全球预测 2025-2030

Prostate Health Market by Disease Type (Benign Prostatic Hyperplasia, Prostate Cancer, Prostatitis), Therapy Type (AR-Directed Therapies, Cytotoxic Agents, Hormone ADT), Drug Treatment Type - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

摄护腺健康市场2023年估值为521.3亿美元，预计到2024年将达到574.8亿美元，复合年增长率为10.74%，到2030年将达到1064.9亿美元。

摄护腺健康市场包括旨在维持和改善摄护腺健康的产品、服务和治疗。这包括针对良性前列腺增生 (BPH)、前列腺炎和前列腺癌等疾病的药物、外科手术、诊断、营养食品和医疗设备。由于人口老化和生活方式因素，前列腺相关疾病的盛行率不断上升，支持了对该市场的需求。治疗应用范围从预防保健到高级治疗方法，最终用途包括医院、专科诊所、研究机构和患者自我护理。主要的市场驱动因素包括诊断和治疗方法的技术进步、意识的提高以及医疗保健支出的增加。然而，高昂的治疗费用、药物和治疗的副作用以及保险范围问题等限制因素给市场扩张带来了挑战。潜在的商机在于个人化医疗、用于远距患者管理的远端医疗以及微创手术的创新，这些创新越来越受到关注。公司可以透过投资研发、建立策略伙伴关係以及利用数位平台来加强患者教育和参与来利用这些优势。然而，新药认证的监管限制以及多方争夺市场占有率的竞争格局等挑战尤其需要谨慎处理。创新可能会致力于开发更有效、侵入性更小的诊断工具，并促进生技药品和基因疗法的突破，从而有可能改变治疗模式。此外，促进学术机构和生物技术公司之间的合作可以刺激研究并促进从实验室到临床的转变。在技​​术不断进步以及患者和医疗保健提供者偏好不断变化的推动下，市场的动态本质要求策略制定具有敏捷性和远见。因此，公司应该关注适应性经营模式，确保灵活性和对新趋势和消费者需求的应对力。

主要市场统计
基准年[2023] 521.3亿美元
预测年份 [2024] 574.8亿美元
预测年份 [2030] 1064.9亿美元
复合年增长率（%） 10.74%

市场动态：揭示快速发展的前列腺健康市场的关键市场洞察

供需的动态交互作用正在改变前列腺健康市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助企业了解消费行为及其对製造业的影响。

  • 市场驱动因素
    • 人口老化加剧以及良性前列腺增生和前列腺癌盛行率增加
    • 政府加大倡议推动诊断技术
    • 荷尔蒙疗法的技术创新以及基因组学和蛋白​​质组学的进步
  • 市场限制因素
    • 与良性摄护腺增生药物相关的副作用
  • 市场机会
    • 增加研究导致开发新药，如 rucaparib 和 olaparib
    • 开发前列腺癌新治疗方法
  • 市场挑战
    • 对摄护腺健康缺乏认识

波特五力：驾驭摄护腺健康市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解摄护腺健康市场的外部影响

外部宏观环境因素在塑造前列腺健康市场的表现动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解摄护腺健康市场的竞争格局

对前列腺健康市场的详细市场占有率分析可以对供应商绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来发现自己的竞争定位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵摄护腺健康市场供应商的绩效评估

FPNV定位矩阵是评估摄护腺健康市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议绘製前列腺健康市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对前列腺健康市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：全面分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监管核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点关注可望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 人口老化加剧，良性前列腺增生和前列腺癌发生率增加
      • 扩大政府努力改善诊断技术
      • 荷尔蒙疗法药物创新以及基因组学和蛋白​​质组学开发
    • 抑制因素
      • 与 BPH 治疗药物相关的副作用
    • 机会
      • 增加研究导致开发新药，如 rucaparib 和 olaparib
      • 开发前列腺癌新治疗方法
    • 任务
      • 摄护腺健康意识淡薄
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章前列腺保健市场：依疾病类型

  • 良性摄护腺增生
  • 摄护腺癌
  • 摄护腺炎

第七章前列腺保健市场治疗类型

  • AR导向疗法
  • 细胞毒性药物
  • 荷尔蒙ADT
  • 聚（ADP-核糖）聚合酵素（PARP）抑制剂

第八章按药物治疗类型分類的前列腺保健市场

  • 5-α还原酶抑制剂
    • 度他雄胺
    • Finasteride
  • α阻断剂
    • 阿夫唑嗪
    • 多沙唑嗪
    • 西洛多辛
    • Tamsulosin

第九章美洲前列腺保健市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第10章亚太地区前列腺保健市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章欧洲、中东和非洲前列腺保健市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Elekta AB
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Ferring Pharmaceuticals Inc.
  • GlaxoSmithKline PLC
  • Ipsen Limited
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Company Ltd.
Product Code: MRR-8201ABF20E0C

The Prostate Health Market was valued at USD 52.13 billion in 2023, expected to reach USD 57.48 billion in 2024, and is projected to grow at a CAGR of 10.74%, to USD 106.49 billion by 2030.

The prostate health market encompasses products, services, and treatments aimed at maintaining or improving the health of the prostate gland. This includes pharmaceuticals, surgical procedures, diagnostics, dietary supplements, and medical devices targeting conditions such as benign prostatic hyperplasia (BPH), prostatitis, and prostate cancer. The necessity of this market is underscored by the increasing prevalence of prostate-related disorders, fueled by aging populations and lifestyle factors. Applications span from preventive healthcare to advanced treatment methods, with end-use encompassing hospitals, specialty clinics, research institutes, and patient self-care. Key market growth drivers include technological advancements in diagnostics and treatment modalities, increasing awareness, and heightened healthcare expenditure. However, limitations such as high treatment costs, side effects of medications and procedures, and insurance coverage issues challenge market expansion. Potential opportunities lie in personalized medicine, telemedicine for remote patient management, and innovations in minimally invasive procedures, which are increasingly gaining traction. Businesses can capitalize on these by investing in R&D, forming strategic partnerships, and leveraging digital platforms for enhanced patient education and engagement. Nonetheless, challenges such as regulatory constraints, particularly on new drug approvals, and the competitive landscape with several players vying for market share, require careful navigation. Innovation could be directed towards developing more effective and less invasive diagnostic tools, and fostering breakthroughs in biologics and gene therapy with the potential to revolutionize treatment paradigms. Furthermore, fostering collaborations between academic institutions and biotech companies can spur research and expedite translation from bench to bedside. The nature of the market is dynamic, driven by constant advancements in technology and shifts in patient and healthcare provider preferences, necessitating agility and foresight in strategy formulation. Companies should thus focus on adaptive business models, ensuring flexibility and responsiveness to emerging trends and consumer needs.

KEY MARKET STATISTICS
Base Year [2023] USD 52.13 billion
Estimated Year [2024] USD 57.48 billion
Forecast Year [2030] USD 106.49 billion
CAGR (%) 10.74%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Prostate Health Market

The Prostate Health Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising aging population and increasing prevalence rate of benign prostatic hyperplasia and prostate cancer
    • Growing government's initiatives for advancement in technology in diagnosis
    • Innovation in hormone therapy drugs and developments genomics and proteomics
  • Market Restraints
    • Side-effects associated with BPH medications
  • Market Opportunities
    • Increasing researches leading to development of new drugs like Rucaparib and Olaparib
    • Development of novel modality of therapy for prostate cancer
  • Market Challenges
    • Low awareness regarding prostate health

Porter's Five Forces: A Strategic Tool for Navigating the Prostate Health Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Prostate Health Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Prostate Health Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Prostate Health Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Prostate Health Market

A detailed market share analysis in the Prostate Health Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Prostate Health Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Prostate Health Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Prostate Health Market

A strategic analysis of the Prostate Health Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Prostate Health Market, highlighting leading vendors and their innovative profiles. These include Astellas Pharma Inc., AstraZeneca PLC, Bayer AG, Bristol-Myers Squibb Company, Elekta AB, Eli Lilly and Company, F. Hoffmann-La Roche AG, Ferring Pharmaceuticals Inc., GlaxoSmithKline PLC, Ipsen Limited, Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi S.A., and Takeda Pharmaceutical Company Ltd..

Market Segmentation & Coverage

This research report categorizes the Prostate Health Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Disease Type, market is studied across Benign Prostatic Hyperplasia, Prostate Cancer, and Prostatitis.
  • Based on Therapy Type, market is studied across AR-Directed Therapies, Cytotoxic Agents, Hormone ADT, and Poly (ADP-Ribose) Polymerase (PARP) Inhibitors.
  • Based on Drug Treatment Type, market is studied across 5-Alpha Reductase Inhibitors and Alpha Blockers. The 5-Alpha Reductase Inhibitors is further studied across Dutasteride and Finasteride. The Alpha Blockers is further studied across Alfuzosin, Doxazosin, Silodosin, and Tamsulosin.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising aging population and increasing prevalence rate of benign prostatic hyperplasia and prostate cancer
      • 5.1.1.2. Growing government's initiatives for advancement in technology in diagnosis
      • 5.1.1.3. Innovation in hormone therapy drugs and developments genomics and proteomics
    • 5.1.2. Restraints
      • 5.1.2.1. Side-effects associated with BPH medications
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing researches leading to development of new drugs like Rucaparib and Olaparib
      • 5.1.3.2. Development of novel modality of therapy for prostate cancer
    • 5.1.4. Challenges
      • 5.1.4.1. Low awareness regarding prostate health
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Prostate Health Market, by Disease Type

  • 6.1. Introduction
  • 6.2. Benign Prostatic Hyperplasia
  • 6.3. Prostate Cancer
  • 6.4. Prostatitis

7. Prostate Health Market, by Therapy Type

  • 7.1. Introduction
  • 7.2. AR-Directed Therapies
  • 7.3. Cytotoxic Agents
  • 7.4. Hormone ADT
  • 7.5. Poly (ADP-Ribose) Polymerase (PARP) Inhibitors

8. Prostate Health Market, by Drug Treatment Type

  • 8.1. Introduction
  • 8.2. 5-Alpha Reductase Inhibitors
    • 8.2.1. Dutasteride
    • 8.2.2. Finasteride
  • 8.3. Alpha Blockers
    • 8.3.1. Alfuzosin
    • 8.3.2. Doxazosin
    • 8.3.3. Silodosin
    • 8.3.4. Tamsulosin

9. Americas Prostate Health Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Prostate Health Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Prostate Health Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Astellas Pharma Inc.
  • 2. AstraZeneca PLC
  • 3. Bayer AG
  • 4. Bristol-Myers Squibb Company
  • 5. Elekta AB
  • 6. Eli Lilly and Company
  • 7. F. Hoffmann-La Roche AG
  • 8. Ferring Pharmaceuticals Inc.
  • 9. GlaxoSmithKline PLC
  • 10. Ipsen Limited
  • 11. Merck & Co., Inc.
  • 12. Novartis AG
  • 13. Pfizer Inc.
  • 14. Sanofi S.A.
  • 15. Takeda Pharmaceutical Company Ltd.

LIST OF FIGURES

  • FIGURE 1. PROSTATE HEALTH MARKET RESEARCH PROCESS
  • FIGURE 2. PROSTATE HEALTH MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL PROSTATE HEALTH MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL PROSTATE HEALTH MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL PROSTATE HEALTH MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS PROSTATE HEALTH MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS PROSTATE HEALTH MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES PROSTATE HEALTH MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES PROSTATE HEALTH MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC PROSTATE HEALTH MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC PROSTATE HEALTH MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA PROSTATE HEALTH MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA PROSTATE HEALTH MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. PROSTATE HEALTH MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. PROSTATE HEALTH MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. PROSTATE HEALTH MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL PROSTATE HEALTH MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL PROSTATE HEALTH MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL PROSTATE HEALTH MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. PROSTATE HEALTH MARKET DYNAMICS
  • TABLE 7. GLOBAL PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL PROSTATE HEALTH MARKET SIZE, BY BENIGN PROSTATIC HYPERPLASIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL PROSTATE HEALTH MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL PROSTATE HEALTH MARKET SIZE, BY PROSTATITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL PROSTATE HEALTH MARKET SIZE, BY AR-DIRECTED THERAPIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL PROSTATE HEALTH MARKET SIZE, BY CYTOTOXIC AGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL PROSTATE HEALTH MARKET SIZE, BY HORMONE ADT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL PROSTATE HEALTH MARKET SIZE, BY POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL PROSTATE HEALTH MARKET SIZE, BY DUTASTERIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL PROSTATE HEALTH MARKET SIZE, BY FINASTERIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL PROSTATE HEALTH MARKET SIZE, BY ALFUZOSIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL PROSTATE HEALTH MARKET SIZE, BY DOXAZOSIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL PROSTATE HEALTH MARKET SIZE, BY SILODOSIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL PROSTATE HEALTH MARKET SIZE, BY TAMSULOSIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS PROSTATE HEALTH MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. CANADA PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 47. CANADA PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 48. MEXICO PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. MEXICO PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. MEXICO PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. MEXICO PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 52. MEXICO PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 53. UNITED STATES PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 58. UNITED STATES PROSTATE HEALTH MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 59. ASIA-PACIFIC PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC PROSTATE HEALTH MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 65. AUSTRALIA PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. AUSTRALIA PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. AUSTRALIA PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. AUSTRALIA PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 69. AUSTRALIA PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 70. CHINA PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. CHINA PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. CHINA PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. CHINA PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 74. CHINA PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 75. INDIA PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. INDIA PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. INDIA PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. INDIA PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 79. INDIA PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 80. INDONESIA PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. INDONESIA PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. INDONESIA PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. INDONESIA PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 84. INDONESIA PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 85. JAPAN PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. JAPAN PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. JAPAN PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. JAPAN PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 89. JAPAN PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 90. MALAYSIA PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. MALAYSIA PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. MALAYSIA PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. MALAYSIA PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 94. MALAYSIA PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 95. PHILIPPINES PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. PHILIPPINES PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. PHILIPPINES PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. PHILIPPINES PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 99. PHILIPPINES PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 100. SINGAPORE PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. SINGAPORE PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. SINGAPORE PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. SINGAPORE PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 104. SINGAPORE PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 105. SOUTH KOREA PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. SOUTH KOREA PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. SOUTH KOREA PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. SOUTH KOREA PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 109. SOUTH KOREA PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 110. TAIWAN PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. TAIWAN PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. TAIWAN PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. TAIWAN PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 114. TAIWAN PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 115. THAILAND PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. THAILAND PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. THAILAND PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. THAILAND PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 119. THAILAND PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 120. VIETNAM PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. VIETNAM PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. VIETNAM PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. VIETNAM PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 124. VIETNAM PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA PROSTATE HEALTH MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 131. DENMARK PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. DENMARK PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. DENMARK PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. DENMARK PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 135. DENMARK PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 136. EGYPT PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. EGYPT PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. EGYPT PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. EGYPT PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 140. EGYPT PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 141. FINLAND PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. FINLAND PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. FINLAND PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. FINLAND PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 145. FINLAND PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 146. FRANCE PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. FRANCE PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. FRANCE PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. FRANCE PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 150. FRANCE PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 151. GERMANY PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. GERMANY PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. GERMANY PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. GERMANY PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 155. GERMANY PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 156. ISRAEL PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. ISRAEL PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. ISRAEL PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. ISRAEL PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 160. ISRAEL PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 161. ITALY PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. ITALY PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. ITALY PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. ITALY PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 165. ITALY PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 166. NETHERLANDS PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. NETHERLANDS PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. NETHERLANDS PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. NETHERLANDS PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 170. NETHERLANDS PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 171. NIGERIA PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. NIGERIA PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. NIGERIA PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. NIGERIA PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 175. NIGERIA PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 176. NORWAY PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. NORWAY PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. NORWAY PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. NORWAY PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 180. NORWAY PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 181. POLAND PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. POLAND PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. POLAND PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. POLAND PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 185. POLAND PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 186. QATAR PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. QATAR PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. QATAR PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. QATAR PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 190. QATAR PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 191. RUSSIA PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 192. RUSSIA PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 193. RUSSIA PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 194. RUSSIA PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 195. RUSSIA PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 196. SAUDI ARABIA PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 197. SAUDI ARABIA PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 198. SAUDI ARABIA PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 199. SAUDI ARABIA PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 200. SAUDI ARABIA PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 201. SOUTH AFRICA PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 202. SOUTH AFRICA PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH AFRICA PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 204. SOUTH AFRICA PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 205. SOUTH AFRICA PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 206. SPAIN PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 207. SPAIN PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 208. SPAIN PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 209. SPAIN PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 210. SPAIN PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 211. SWEDEN PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 212. SWEDEN PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 213. SWEDEN PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 214. SWEDEN PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 215. SWEDEN PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 216. SWITZERLAND PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 217. SWITZERLAND PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 218. SWITZERLAND PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 219. SWITZERLAND PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 220. SWITZERLAND PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 221. TURKEY PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 222. TURKEY PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 223. TURKEY PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 224. TURKEY PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 225. TURKEY PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 226. UNITED ARAB EMIRATES PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 227. UNITED ARAB EMIRATES PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED ARAB EMIRATES PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED ARAB EMIRATES PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED ARAB EMIRATES PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED KINGDOM PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED KINGDOM PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED KINGDOM PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED KINGDOM PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED KINGDOM PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 236. PROSTATE HEALTH MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 237. PROSTATE HEALTH MARKET, FPNV POSITIONING MATRIX, 2023